Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/PACTR202607754538830
PACTR202607754538830RecruitingPhase 3

Clinical Evaluation of Glycerol-Preserved Human Amniotic Membrane Versus Nanocrystalline Silver Dressing (Acticoat®) in Partial-Thickness Burns: A Prospective Within-Patient Randomised Controlled Trial

University of the Witwatersrand0 sites75 target enrollmentStarted: October 1, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Enrollment
75
Study OverviewEligibility CriteriaArms & InterventionsInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
6 Year(s) to 12 Year(s) (—)
Sex
All

Inclusion Criteria

  • •Patients aged =8 years presenting within 72 hours of acute partial thickness burn injury.
  • •If they had two anatomically comparable wound sites suitable for within-patient comparison (bilateral/symmetric burns, or a single wound of sufficient area for division into two equivalent halves).
  • •Eligible sites included wounds (burns or donor sites) on the limbs, torso, face, hands, or perineum.

Exclusion Criteria

  • •Patients with physical and/or mental conditions that are not expected to comply with the investigation.
  • •Participation in other clinical investigation(s) within 1 month prior to and at the start of the investigation.
  • •Patients with poor prognosis or who are critically ill.
  • •Patients with full thickness burns or infected wounds.

Arms & Interventions

;Glycerol preserved human amniotic membrane;Acticoat

Intervention: ;Glycerol preserved human amniotic membrane;Acticoat

Investigators

Similar Trials

Not yet recruiting
Not Applicable
Study to Evaluate the Safety and Efficacy of Asciminib in Pediatric Patients With Ph+ CML-CP (CABL001I12202)Pediatric Patients With Ph+ CML-CP
jRCT20312602653
Completed
Phase 4
Study to assess the relative bioavailability of Neludolat versus YAZ in healthy female subjects.Healthy subjects
2025-524871-22-00Pevisal Group Farmaceutici S.r.l.24
Recruiting
Phase 4
The pilot bioavailability study comparing the absorption of carbetocin (which is used as prevention of heavy bleeding after childbirth) in PABAL 100 μg/mL Solution for Injection when administered sublingually in the dose of 500 μg and intramuscularly in the dose of 100 μg.Not applicable (submitted trial is a bioavalability study in healthy participants).
2025-524768-39-00Oxytone Bioscience B.V.4
Recruiting
Phase 1
Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid TumorsDose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.
2023-509047-26-00Amgen Inc.135
Recruiting
Phase 1
A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancersAdvanced solid tumors (cutaneous melanoma, mucosal melanoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, or basal cell carcinoma)
2025-522402-21-00Kupando GmbH21